title: Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa.
abstract: Eight patients with ocular adnexal mucosal-associated lymphpid tissue (MALT) lymphoma were treated with rituximab, at diagnosis (n=5) or relapse (n=3). All untreated patients achieved lymphoma regression, while relapsing patients had no benefit. Four responding patients experienced early relapse. The median time to progression was 5 months. The efficacy of rituximab in ocular adnexal lymphoma is lower than that reported for gastric MALT lymphomas.
authors.forename: Andrés J M
authors.initials: AJ
authors.lastname: Ferreri
authors.forename: Maurilio
authors.initials: M
authors.lastname: Ponzoni
authors.forename: Giovanni
authors.initials: G
authors.lastname: Martinelli
authors.forename: Giuliana
authors.initials: G
authors.lastname: Muti
authors.forename: Massimo
authors.initials: M
authors.lastname: Guidoboni
authors.forename: Riccardo
authors.initials: R
authors.lastname: Dolcetti
authors.forename: Claudio
authors.initials: C
authors.lastname: Doglioni
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D005134:Eye Neoplasms / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab